Skip to main content
. Author manuscript; available in PMC: 2013 Nov 25.
Published in final edited form as: Cell Prolif. 2011 Jun 6;44(4):10.1111/j.1365-2184.2011.00757.x. doi: 10.1111/j.1365-2184.2011.00757.x

Figure 3. CXCL13 regulates activation of Akt and ERK1/2.

Figure 3

FACE assays were performed to measure active and total Akt or ERK1/2 in LNCaP and PC3 cell lines. Cells were treated with isotype control antibody or anti-human CXCR5 antibody (1 μg/ml), DOCK2 siRNA or control siRNA (2 μM), or JNK inhibitor (10 μM) in the presence of CXCL13 (100 ng/ml) for 0, 5 or 10 min. Experiments were performed in triplicate and results show ratios of active (phosphorylated) to total Akt or ERK1/2. Error bars represent ± standard error of means of three independent experiments. *Significant (P < 0.05) decrease in phosphorylation.